Ligand Pharmaceuticals Incorporated

Company Profile

Ligand Pharmaceuticals Incorporated had its IPO on 1992-11-18 under the ticker symbol LGND.

The company operates in the Healthcare sector and Biotechnology industry. Ligand Pharmaceuticals Incorporated has a staff strength of 76 employees.

Stock update

Shares of Ligand Pharmaceuticals Incorporated opened at $63.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $62.47 - $63.54, and closed at $62.71.

This is a -1.45% slip from the previous day's closing price.

A total volume of 76,595 shares were traded at the close of the day’s session.

In the last one week, shares of Ligand Pharmaceuticals Incorporated have slipped by -5.76%.

Ligand Pharmaceuticals Incorporated's Key Ratios

Ligand Pharmaceuticals Incorporated has a market cap of $1.10 billion, indicating a price to book ratio of 1.3264 and a price to sales ratio of 4.3445.

In the last 12-months Ligand Pharmaceuticals Incorporated’s revenue was $179.95 million with a gross profit of $107.34 million and an EBITDA of $47.28 million. The EBITDA ratio measures Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ligand Pharmaceuticals Incorporated’s operating margin was 2.48% while its return on assets stood at 0.3% with a return of equity of 5.59%.

In Q2, Ligand Pharmaceuticals Incorporated’s quarterly earnings growth was a negative -97.5% while revenue growth was a negative 47.4%.

Ligand Pharmaceuticals Incorporated’s PE and PEG Ratio

Forward PE

31.1526

Trailing PE

28.1549

PEG

1.2475

Its diluted EPS in the last 12-months stands at $2.26 per share while it has a forward price to earnings multiple of 31.1526 and a PEG multiple of 1.2475. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ligand Pharmaceuticals Incorporated’s profitability.

Ligand Pharmaceuticals Incorporated stock is trading at a EV to sales ratio of 4.4489 and a EV to EBITDA ratio of 33.3185. Its price to sales ratio in the trailing 12-months stood at 4.3445.

Ligand Pharmaceuticals Incorporated stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$758.11 million

Total Liabilities

$29.39 million

Operating Cash Flow

$7.56 million

Capital Expenditure

$203000

Dividend Payout Ratio

0%

Ligand Pharmaceuticals Incorporated ended 2024 with $758.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $758.11 million while shareholder equity stood at $664.89 million.

Ligand Pharmaceuticals Incorporated ended 2024 with $27.67 million in deferred long-term liabilities, $29.39 million in other current liabilities, 17000.00 in common stock, $495.10 million in retained earnings and $431.05 million in goodwill. Its cash balance stood at $219.04 million and cash and short-term investments were $219.04 million. The company’s total short-term debt was $680,000 while long-term debt stood at $0.

Ligand Pharmaceuticals Incorporated’s total current assets stands at $276.71 million while long-term investments were $0 and short-term investments were $190.60 million. Its net receivables were $27.99 million compared to accounts payable of $16.87 million and inventory worth $26.91 million.

In 2024, Ligand Pharmaceuticals Incorporated's operating cash flow was $7.56 million while its capital expenditure stood at $203000.

Comparatively, Ligand Pharmaceuticals Incorporated paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$62.71

52-Week High

$85.7

52-Week Low

$49.4284

Analyst Target Price

$112.67

Ligand Pharmaceuticals Incorporated stock is currently trading at $62.71 per share. It touched a 52-week high of $85.7 and a 52-week low of $85.7. Analysts tracking the stock have a 12-month average target price of $112.67.

Its 50-day moving average was $67.05 and 200-day moving average was $70.8 The short ratio stood at 9.41 indicating a short percent outstanding of 0%.

Around 564.9% of the company’s stock are held by insiders while 8996.1% are held by institutions.